Evidence map›Paper›PMID 41152284›Full record

ArticleScientific reports2025

RNA-seq analysis of wild-type and mutated TBPL1 gene in breast cancer cells lines through CRISPR/Cas9 approach reveals novel molecular signatures.

Rabia Mishal, Jorge Meléndez-Zajgla, Bertha Rueda-Zarazúa, María Luisa Labra-Barrios, Carlos Alberto Castañón-Sánchez, Salvador Uribe Carvajal, Laura Padierna-Mota, José Manuel Hernández-Hernández, Gloria Leon-Avila, Armando Pérez Rangel and 4 more

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Rabia MishalDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Jorge Meléndez-ZajglaLaboratory of Functional Genomics of Cancer, National Institute of Genomic Medicine (INMEGEN), Periferico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico.
Bertha Rueda-ZarazúaLaboratory of Functional Genomics of Cancer, National Institute of Genomic Medicine (INMEGEN), Periferico Sur 4809, Arenal Tepepan, Tlalpan, 14610, Mexico City, Mexico.
María Luisa Labra-BarriosDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Carlos Alberto Castañón-SánchezLaboratory of Biomedical Research, Subdirección de Enseñanza e Investigación, Regional High Specialty Hospital of Oaxaca, C. Aldama s/n, Paraje "El Tule, 71294, San Bartolo Coyotepec, Oaxaca, Mexico.
Salvador Uribe CarvajalDepartment of Molecular Genetics, Institute of Cellular Physiology, National Autonomous University of Mexico (UNAM), Mexico City, Mexico.
Laura Padierna-MotaLaboratorios de Especialidades Inmunológicas (LEI), Av. Gran Canal s/n, Locales 3 y 4, Ampliación Casas Alemán, Alcaldía Gustavo A. Madero, 07580, Mexico City, Mexico.
José Manuel Hernández-HernándezDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Gloria Leon-AvilaDepartmento de Zoología, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional (ENCB-IPN), Unidad Profesional Lázaro Cárdenas, Prolongación de Carpio y Plan de Ayala s/n, Col. Santo Tomás, Alcaldía Miguel Hidalgo Mexico City, 11340, Mexico City, Mexico.
Armando Pérez RangelDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Edgar Hernández-MartínezDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Erika Beatriz Angeles-MoralesDepartmento de Microbiología, Escuela Nacional de Ciencias Biológicas del Instituto Politécnico Nacional (ENCB-IPN), Unidad Profesional Lázaro Cárdenas, Prolongación de Carpio y Plan de Ayala s/n, Col. Santo Tomás, Alcaldía Miguel Hidalgo Mexico City, 11340, Mexico City, Mexico.
Ibrahim Khalil AlbalawiDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico.
Juan Pedro Luna-AriasDepartment of Cell Biology, Center for Research and Advanced Studies of the National Polytechnic Institute (Cinvestav), Av. IPN 2508, Col. San Pedro Zacatenco, Alcaldía Gustavo A. Madero, 07360, Mexico City, Mexico. jpluna@cinvestav.mx.

Funding

Consejo Nacional de Humanidades, Ciencia y Tecnologia, Mexico Ph.D. fellowship 465228Consejo Nacional de Humanidades, Ciencia y Tecnología, Mexico Ciencia de Frontera 2019_Proyecto No. 116337Consejo Nacional de Humanidades, Ciencia y Tecnología, Mexico PhD. fellowship 752614
6 · The paper itself

Abstract

Breast cancer is the leading cause of death among women globally. Several genes have been found to be transcriptionally dysregulated in cancer, according to recent studies. TATA-box binding protein (TBP) and its two paralogs, TBPL1 and TBPL2, play roles in human transcription. The TBPL1 gene is implicated in colorectal carcinomas by suppressing the expression of miR-18a. However, its function in breast cancer remains undisclosed. TBPL1 is distantly related to TBP and possesses a 40% similarity with TBP's core domain. In the present study, we explored the potential role of the TBPL1 gene in transcriptome regulation by knocking out the TBPL1 gene through the CRISPR/Cas9 method. Following the knockout of the TBPL1 gene, we examined the gene transcription patterns and compared them to wild-type cell lines. We observed disparate signatures of upregulated and downregulated genes in wild-type and mutated conditions. Healthy breast MCF-12F, and T47D, SKBR3, and MDA-MB-231 breast cancer cell lines were assessed, as these cancer cells exhibit overexpression of the TBPL1 gene. Next-generation sequencing data revealed distinct marker genes regulated by the TBPL1 gene and their potential involvement in cell migration, proliferation, anti-apoptosis, and metastasis. Additionally, we also discovered novel lncRNAs implicated in the transcriptome analysis of the TBPL1 knocked-out gene. Our investigation indicated that this gene might affect varied stages of breast cancer cell lines' cellular properties, such as cell duplication, morphology, and growth. It might also contribute to tumor formation in more aggressive cell lines like MDA-MB-231 in vivo.

Indexed as

Breast NeoplasmsCRISPR-Cas SystemsMutationTATA-Box Binding ProteinCell Line, TumorCell MovementCell ProliferationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansRNA-SeqTranscriptomeTATA-Box Binding ProteinBreast cancer cell linesCRISPR/Cas9Gene expression profilesTBP familyTBPL1 knockout

Identifiers

PMID41152284
PMCPMC12568972

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.